Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Prevalence of BTK and PLCγ2 mutations in CLL relapsing under ibrutinib

Paolo Ghia • 21 Jun 2020
EHA 2020
Chronic Lymphocytic Leukemia Leukemia Ibrutinib

Paolo Ghia, MD, of the Università Vita-Salute San Raffaele, Milan, Italy, discusses an ERIC study evaluating the incidence of BTK and PLCγ2 (phospholipase C Gamma 2) mutations in ibrutinib refractory chronic lymphocytic leukemia (CLL) patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Paolo Ghia

1:21
Monoclonal B-cell lymphocytosis: a disease to be (or not to be)
Paolo Ghia • 7 Apr 2024
MBL: biology, classification & the possibility of early interception
Andrew Rawstron et al. • 25 Mar 2024
2:20
Monoclonal B-cell lymphocytosis: at a crossroad between disease and senescence
Paolo Ghia • 8 Dec 2023
3:00
Five-year follow-up of the CAPTIVATE trial: ibrutinib retreatment in patients with CLL
Paolo Ghia • 8 Dec 2023

Related Videos

1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals